PUBLIC COMPANY
savePYC Therapeutics Ltd
updated 13d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
- phase1Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
- phase1MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
- —Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
- phase2Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
- phase1SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
- phase2A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
- —Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that